Table 1 Baseline Clinical Characteristics among Participants in the CRISIS Clinical Trial.

From: Circulating CD40 and sCD40L Predict Changes in Renal Function in Subjects with Chronic Kidney Disease

Characteristics*

High sCD40L (>205.0 [142.4, 324.6] pg/mL) (n = 122)

Low sCD40L (≤205.0 [142.4, 324.6] pg/mL) (n = 121)

P-value

High sCD40R (>81.4 [50.9, 306.0] pg/mL) (n = 122)

Low sCD40R (≤81.4 [50.9, 306.0] pg/mL) (n = 121)

P-value

Age (yr)

65.84 ± 14.99

66.05 ± 13.54

0.91

63.80 ± 15.69

68.10 ± 12.34

0.02

Male

74 (61%)

71 (59%)

0.79

76 (62%)

69 (57%)

0.48

Body mass index (kg/m2)

27.38 ± 5.68

28.41 ± 5.11

0.17

27.37 ± 4.57

28.53 ± 6.14

0.13

Smoking (current)

15 (12%)

12 (10%)

0.56

13 (11%)

14 (12%)

0.82

Systolic BP (mmHg)

136.76 ± 20.87

136.87 ± 20.18

0.97

134.8 ± 20.61

138.8 ± 20.25

0.12

Diastolic BP (mmHg)

74.79 ± 12.66

71.74 ± 11.26

0.04

73.93 ± 13.42

72.60 ± 10.53

0.39

MDRD eGFR (ml/min per 1.73 m2)

28.76 ± 14.70

29.30 ± 15.19

0.78

29.30 ± 14.62

30.02 ± 15.63

0.71

CKD-EPI eGFR (ml/min per 1.73 m2)

31.56 ± 17.67

32.02 ± 18.1

0.84

31.34 ± 17.4

32.24 ± 18.4

0.69

Urine protein (mg/dL)

60.78 ± 111.23

54.09 ± 105.96

0.63

61.96 ± 124.5

52.90 ± 89.79

0.52

Creatinine (mg/dL)

2.83 ± 1.68

2.74 ± 1.60

0.68

2.82 ± 1.61

2.75 ± 1.67

0.75

History of Myocardial infarction

18 (15%)

23 (19%)

0.40

23 (19%)

18 (15%)

0.51

History of Angina

23 (19%)

25 (21%)

0.87

25 (20%)

23 (19%)

0.92

History of CVA

12 (10%)

6 (5%)

0.22

6 (5%)

12 (10%)

0.21

History of TIA

11 (9%)

10 (8%)

>0.99

7 (6%)

14 (12%)

0.16

History of Diabetes mellitus

37 (30%)

42 (35%)

0.50

33 (27%)

46 (38%)

0.09

History of Peripheral vascular disease

22 (18%)

23 (19%)

0.87

20 (16%)

25 (21%)

0.49

ACEi

43 (35%)

52 (43%)

0.24

51 (42%)

44 (36%)

0.46

ARB

31 (25%)

30 (25%)

>0.99

24 (20%)

37 (31%)

0.07

ACEi or ARB

77 (64%)

71 (58%)

0.43

74 (61%)

74 (61%)

>0.99

β-Blocker

36 (30%)

36 (30%)

>0.99

38 (31%)

34 (28%)

0.70

Diuretic

53 (43%)

59 (49%)

0.44

61 (50%)

51 (42%)

0.27

Statin

68 (56%)

72 (60%)

0.60

63 (52%)

77 (64%)

0.08

Aspirin

55 (45%)

48 (40%)

0.44

37 (30%)

66 (55%)

<0.001

Mean sCD40L (pg/mL)

479 ± 644

137 ± 37

<0.001

357 ± 652

261 ± 212

0.12

Mean sCD40R (pg/mL)

662 ± 1940

596 ± 2047

0.80

1200 ± 2695

53 ± 13

<0.001

Mean log sCD40L

5.93 ± 0.56

4.88 ± 0.30

<0.001

5.46 ± 0.76

5.35 ± 0.61

0.21

Mean log sCD40R

5.04 ± 1.41

4.82 ± 1.34

0.22

5.91 ± 1.34

3.94 ± 0.24

<0.001

Primary renal disease

DM

22 (18%)

18 (15%)

0.70

16 (13%)

24 (20%)

0.59

APKD

5 (4%)

11 (9%)

0.29

10 (8%)

6 (5%)

0.39

GN/VAS

14 (11%)

18 (15%)

0.74

18 (15%)

14 (12%)

0.50

Pyelonephritis

12 (10%)

4 (3%)

0.11

10 (8%)

6 (5%)

0.39

VAS/HTN

41 (34%)

42 (35%)

 

39 (32%)

44 (36%)

 

Other

28 (23%)

28 (23%)

>0.99

29 (24%)

27 (22%)

0.70

  1. Subjects are stratified by median plasma levels of sCD40L or sCD40R.
  2. *Data are expressed as the mean ± SD or number (percentage). Comparisons were evaluated using two sample t-test for continuous data and Fisher’s exact test for categorical data.
  3. Abbreviations: sCD40L, soluble CD40 ligand; sCD40R, soluble CD40 receptor; yr, year; m, meter; kg, kilogram; BP, blood pressure; MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; CVD, cerebral vascular accident; TIA, transient ischemic accident; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; and β-Blocker, beta adrenergic blocker
  4. DM, diabetic glomerularnephritis; APKD, adult polycystic kidney disease; GN/VAS, glomerularnephritis vasculitis; VAS/HTN, vascular hypertension.
Back to article page